P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

• A. C. Silva-Pinto,
• R. Colombatti,
• A. Pasanisi,
• F. Arcioni,
• L. DeBonnett,
• W. Soliman,
• R. Sarkar,
• R. D. Cançado

Affiliations

A. C. Silva-Pinto

1 Regional Blood Center, Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto School of Medicine, São Paulo, Brazil

R. Colombatti

2 Azienda Ospedale-Università di Padova, Padova

A. Pasanisi

3 Centro Microcitemia-UOC, Ematologia con trapianto, PO Perrino, Brindisi

F. Arcioni

4 Pediatric Hematology and Oncology with Bone Marrow Transplantation, Azienda Ospedaliera di Perugia, Perugia, Italy

L. DeBonnett

5 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

W. Soliman

6 Novartis Saudi Ltd, Riyadh, Saudi Arabia

R. Sarkar

7 Novartis Healthcare Pvt. Ltd., Hyderabad, India

R. D. Cançado

8 Department of Hematology and Oncology, Santa Casa de São Paulo School of Medicine, São Paulo, Brazil